Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F19%3A00072587" target="_blank" >RIV/65269705:_____/19:00072587 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/19:00112622

Result on the web

<a href="https://academic.oup.com/jac/article-abstract/74/11/3315/5545108?redirectedFrom=fulltext" target="_blank" >https://academic.oup.com/jac/article-abstract/74/11/3315/5545108?redirectedFrom=fulltext</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1093/jac/dkz344" target="_blank" >10.1093/jac/dkz344</a>

Result language

angličtina

Original language name

Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)

Original language description

Background: First-line antifungal treatment for invasive mucormycosis (IM) consists of liposomal amphotericin B. Salvage treatment options are limited and often based on posaconazole oral suspension. With the approval of posaconazole new formulations, patients could benefit from improved pharmacokinetics, safety and tolerability. Objectives: Our aim was to assess the effectiveness of posaconazole new formulations for IM treatment. Methods: We performed a case-matched analysis with proven or probable IM patients from the FungiScope (R) Registry. First-line posaconazole new formulations (1st-POSnew) and first-line amphotericin B plus posaconazole new formulations (1st-AMB+POSnew) cases were matched with first-line amphotericin B-based (1st-AMB) treatment controls. Salvage posaconazole new formulations (SAL-POSnew) cases were matched with salvage posaconazole oral suspension (SAL-POSsusp) controls. Each case was matched with up to three controls (based on severity, haematological/oncological malignancy, surgery and/or renal dysfunction). Results: Five patients receiving 1st-POSnew, 18 receiving 1st-AMB+POSnew and 22 receiving SAL-POSnew were identified. By day 42, a favourable response was reported for 80.0% (n=4/5) of patients receiving 1st-POSnew, for 27.8% (n=5/18) receiving 1st-AMB+POSnew and for 50.0% (n=11/22) receiving SAL-POSnew. Day 42 all-cause mortality of patients receiving posaconazole new formulations was lower compared with controls [20.0% (n=1/5) in 1st-POSnew versus 53.3% (n=8/15) in 1st-AMB; 33.3% (n=6/18) in 1st-AMB+POSnew versus 52.0% (n=26/50) in 1st-AMB; and 0.0% (n=0/22) in SAL-POSnew versus 4.4% (n=2/45) in SAL-POSsusp]. Conclusions: Posaconazole new formulations were effective in terms of treatment response and associated mortality of IM. While posaconazole new formulations may be an alternative for treatment of IM, the limited sample size of our study calls for a cautious interpretation of these observations.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30104 - Pharmacology and pharmacy

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of antimicrobial chemotherapy

ISSN

0305-7453

e-ISSN

—

Volume of the periodical

74

Issue of the periodical within the volume

11

Country of publishing house

GB - UNITED KINGDOM

Number of pages

13

Pages from-to

3315-3327

UT code for WoS article

000498167700027

EID of the result in the Scopus database

—